Inactive Instrument

Portola Pharmaceuticals, Inc. Stock price

Equities

US7370101088

Biotechnology & Medical Research

Dynamic Chart
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Biotechnology Select Industry Index CI
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P TMI Index CI
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Global BMI Index CI
Alexion Pharmaceuticals, Inc. completed the acquisition of the remaining 96.6% stake in Portola Pharmaceuticals, Inc.. CI
Portola Pharmaceuticals, Inc. Receives Written Notice of Termination from Bayer AG CI
Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020 CI
Portola Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Alexion Pharmaceuticals, Inc. entered into non-binding expression of interest to acquire remaining 96.6% stake in Portola Pharmaceuticals, Inc. for $1.4 billion. CI
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer, Inc. Aggress to Terminate the Collaboration and License Agreement Among the Parties CI
Portola Pharmaceuticals, Inc. Announces the Establishment of Permanent J-Code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020 CI
Portola Pharmaceuticals, Inc. Announces Results Demonstrating Andexxa® Was Associated with Low Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds CI
New Data Demonstrates Andexxa Can Provide Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors CI
Transcript : Portola Pharmaceuticals, Inc., Q4 2019 Earnings Call, Feb 26, 2020
Portola Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019 CI
Portola Pharmaceuticals, Inc. Reports Impairment Charge for the Fourth Quarter Ended Dec. 31, 2019 CI
More news
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
More about the company
  1. Stock
  2. Equities
  3. Stock Portola Pharmaceuticals, Inc. - Nasdaq